title: Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.
abstract: Whole-body imaging, in particular molecular imaging with fluorine 18 ((18)F)-fluorodeoxyglucose (FDG) positron emission tomography (PET), is essential to management of lymphoma. The assessment of disease extent provided by use of whole-body imaging is mandatory for planning appropriate treatment and determining patient prognosis. Assessment of treatment response allows clinicians to tailor the treatment strategy during therapy if necessary and to document complete remission at the end of treatment. Because of rapid technical developments, such as echo-planar sequences, parallel imaging, multichannel phased-array surface coils, respiratory gating, and moving examination tables, whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging that reflects cell density is now feasible in routine clinical practice. Whole-body DW MR imaging allows anatomic assessment as well as functional and quantitative evaluation of tumor sites by calculation of the apparent diffusion coefficient (ADC). Because of their high cellularity and high nucleus-to-cytoplasm ratio, lymphomatous lesions have low ADC values and appear hypointense on ADC maps. As a result, whole-body DW MR imaging with ADC mapping has become a promising tool for lymphoma staging and treatment response assessment. The authors review their 4 years of experience with 1.5-T and 3-T whole-body DW MR imaging used with (18)F-FDG PET/computed tomography at baseline, interim, and end of treatment in patients with Hodgkin lymphoma and diffuse large B-cell lymphoma and discuss the spectrum of imaging findings and potential pitfalls, limitations, and challenges associated with whole-body DW MR imaging in these patients.
authors: From the Department of Medical Imaging (S.T.M., A.L., P.Z., L.B., A.R.), Department of Nuclear Medicine (E.I., L.B.), and Lymphoproliferative Unit (K.B., C.H.), AP-HP, Groupe Henri Mondor Albert Chenevier, CHU Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France; Faculty of Medicine, Université Paris Est Creteil, Creteil, France (A.L., E.I., L.B., C.H., A.R.); Neurospin, CEA, Saclay, France (A.V.); and Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Gueishan, Taiwan (C.L.).
authors: Sarah
authors: S
authors: Toledano-Massiah
authors: Alain
authors: A
authors: Luciani
authors: Emmanuel
authors: E
authors: Itti
authors: Pierre
authors: P
authors: Zerbib
authors: Alexandre
authors: A
authors: Vignaud
authors: Karim
authors: K
authors: Belhadj
authors: Laurence
authors: L
authors: Baranes
authors: Corinne
authors: C
authors: Haioun
authors: Chieh
authors: C
authors: Lin
authors: Alain
authors: A
authors: Rahmouni
mesh_terms: D038524:Diffusion Magnetic Resonance Imaging; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000473:pathology* / Q000628:therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology* / Q000628:therapy; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D051598:Whole Body Imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18